Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Glioblastoma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Overweight 2 Obesity 2 Breast Neoplasms 2 Glioma 1 Glioblastoma 1

Interventions

Temozolomide 186 Radiotherapy 109 Bevacizumab 84 Radiation 37 Irinotecan 26 Magnetic Resonance Spectroscopy 25 Carmustine 23 Surgical Procedures, Operative 21 Lomustine 19 Erlotinib Hydrochloride 18 Chemotherapy, Adjuvant 15 Carboplatin 15 sargramostim 11 Drug Therapy 11 temsirolimus 10 Radiosurgery 10 O(6)-benzylguanine 10 pembrolizumab 9 motexafin gadolinium 9 Vorinostat 9 Radiotherapy, Intensity-Modulated 9 Radiotherapy, Conformal 9 Imatinib Mesylate 9 Everolimus 9 Thalidomide 8 Sorafenib 8 Nivolumab 8 Gefitinib 8 cediranib 7 Sirolimus 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡